Participants:0–17 years · 18–64 years
Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker

Contact Research Centre

Graft versus host disease+1

Not recruiting

Investigational

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Investigational

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Itolizumab

Contact Research Centre

Cholangiocarcinoma

Not recruiting

Registered drugNo placebo

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cisplatin

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Transitional cell carcinoma

Not recruiting

Registered drugNo placebo

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Avelumab

Contact Research Centre

Triple negative breast cancer+1

Not recruiting

Registered drugNo placebo

Study of MEN1611 and Eribulin for Advanced Metaplastic Breast Cancer in Patients with PIK3CA/PTEN Alterations

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Eribulin

Contact Research Centre

Multiple system atrophy+1

Not recruiting

Investigational

Study on the Safety and Tolerability of Exidavnemab in Patients with Mild to Moderate Parkinson's Disease

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Exidavnemab

Contact Research Centre

Spinal muscular atrophy

Not recruiting

Investigational

Study of NMD670 tablets to improve muscle strength in adults with Type 3 spinal muscular atrophy who can walk

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Nmd670

Contact Research Centre

Hodgkin's disease

Not recruiting

Registered drugNo placebo

Title: Comparing Brentuximab Vedotin plus ESHAP versus ESHAP alone in treating patients with relapsed or refractory classical Hodgkin's Lymphoma

Registered drugNo placebo

Spain

Participants:18–64 years
Substances:Brentuximab Vedotin

Contact Research Centre

Find therapies in clinical trials near you – page 11

206 trials match your criteria

Multiple sclerosis relapse

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Fallopian tube cancer+2

Study of Relacorilant and Nab-Paclitaxel for Patients with Advanced, Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Facioscapulohumeral muscular dystrophy

Study on the Effectiveness and Safety of Losmapimod for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)

Myotonic dystrophy

Study on AOC 1001 for Treating Myotonic Dystrophy Type 1 in Patients

Graft versus host disease+1

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Cholangiocarcinoma

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Hormone receptor positive HER2 negative breast cancer

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Transitional cell carcinoma

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Triple negative breast cancer+1

Study of MEN1611 and Eribulin for Advanced Metaplastic Breast Cancer in Patients with PIK3CA/PTEN Alterations

Multiple system atrophy+1

Study on the Safety and Tolerability of Exidavnemab in Patients with Mild to Moderate Parkinson's Disease

Spinal muscular atrophy

Study of NMD670 tablets to improve muscle strength in adults with Type 3 spinal muscular atrophy who can walk

Hodgkin's disease

Title: Comparing Brentuximab Vedotin plus ESHAP versus ESHAP alone in treating patients with relapsed or refractory classical Hodgkin's Lymphoma

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.